---
schema_version: "secwatch.filing_event.v1"
accession: "0001822479-24-000038"
form_type: "8-K"
ticker: "SHC"
cik: "0001822479"
company_name: "Sotera Health Co"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:12:47.446557+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Sotera Health Q2 net revenue up 8.3% to $277M; adj. EBITDA up 6.9% to $137M

## Summary
- Net income $9M ($0.03 diluted) vs $24M ($0.08) in Q2 2023; decline due to debt refinancing charges.
- Adjusted EPS $0.19 vs $0.20; higher interest expense weighed on earnings.
- Refinanced debt structure, extending maturities to 2031; reaffirmed 2024 outlook.
- First-half 2024 revenue $525M (+10.3%), adj. EBITDA $249M (+9.8%), adj. EPS $0.32.
- All three segments (Sterigenics, Nordion, Nelson Labs) reported volume increases in Q2.

## SEC filing metadata
- accession: 0001822479-24-000038
- form_type: 8-K
- ticker: SHC
- cik: 0001822479
- company_name: Sotera Health Co
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822479/000182247924000038/0001822479-24-000038-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822479/000182247924000038/shc-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001822479-24-000038
- JSON: https://secwatch.observer/filing/0001822479-24-000038.json
- Plain text: https://secwatch.observer/filing/0001822479-24-000038.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.